

Kirsten Vang Nielsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1416172/publications.pdf>

Version: 2024-02-01

20
papers

636
citations

516710
16
h-index

794594
19
g-index

20
all docs

20
docs citations

20
times ranked

1093
citing authors

#	ARTICLE	IF	CITATIONS
1	Measuring ERCC1 protein expression in cancer specimens: Validation of a novel antibody. Scientific Reports, 2014, 4, 4313.	3.3	16
2	Topoisomerase 1 (TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis. Molecular Oncology, 2013, 7, 101-111.	4.6	20
3	Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial. Clinical Cancer Research, 2013, 19, 1281-1289.	7.0	52
4	An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort. BMC Cancer, 2013, 13, 489.	2.6	5
5	Mechanisms of Topoisomerase I (TOP1) Gene Copy Number Increase in a Stage III Colorectal Cancer Patient Cohort. PLoS ONE, 2013, 8, e60613.	2.5	22
6	Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer. Scandinavian Journal of Gastroenterology, 2012, 47, 340-355.	1.5	24
7	Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status. Molecular Oncology, 2012, 6, 88-97.	4.6	16
8	ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry. Molecular Oncology, 2012, 6, 428-436.	4.6	18
9	TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity. Scandinavian Journal of Gastroenterology, 2012, 47, 68-79.	1.5	26
10	Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Research and Treatment, 2011, 127, 345-355.	2.5	51
11	Re: Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. Journal of the National Cancer Institute, 2011, 103, 352-353.	6.3	7
12	Effects of the Change in Cutoff Values for Human Epidermal Growth Factor Receptor 2 Status by Immunohistochemistry and Fluorescence In Situ Hybridization: A Study Comparing Conventional Brightfield Microscopy, Image Analysis-Assisted Microscopy, and Interobserver Variation. Archives of Pathology and Laboratory Medicine, 2011, 135, 1010-1016.	2.5	29
13	Telomere shortening and chromosomal instability in myelodysplastic syndromes. Genes Chromosomes and Cancer, 2010, 49, 260-269.	2.8	67
14	Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH. Histopathology, 2010, 56, 203-211.	2.9	41
15	Aberrations of ERBB2 and TOP2A genes in breast cancer. Molecular Oncology, 2010, 4, 161-168.	4.6	32
16	Tissue context-activated telomerase in human epidermis correlates with little age-dependent telomere loss. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 297-308.	3.8	32
17	The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncologica, 2008, 47, 725-734.	1.8	101
18	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Journal of Clinical Oncology, 2007, 25, 4020-4020.	1.6	6

#	ARTICLE	IF	CITATIONS
19	SNP genotyping using microsphere-linked PNA and flow cytometric detection. , 2005, 64A, 80-86.		14
20	Short PNA molecular beacons for real-time PCR allelic discrimination of single nucleotide polymorphisms. Molecular and Cellular Probes, 2004, 18, 117-122.	2.1	57